ITCI - Intra-Cellular Therapies, Inc.
| Previous Close | 13.05 |
| Open | 13.05 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 3100 |
| Day's Range | 12.61 - 13.18 |
| 52 Week Range | 10.21 - 23.62 |
| Volume | 259,524 |
| Avg. Volume | 399,285 |
| Market Cap | 673.406M |
| Beta (3Y Monthly) | 1.55 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Insider Monkey•13 hours ago
Here is What Hedge Funds Think About Intra-Cellular Therapies Inc (ITCI)
"Since 2006, value stocks (IVE vs IVW) have underperformed 11 of the 13 calendar years and when they beat growth, it wasn't by much. Cumulatively, through this week, it has been a 122% differential (up 52% for value vs up 174% for growth). This appears to be the longest and most severe drought for value […]
- Simply Wall St.•10 days ago
Before You Buy Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), Consider Its Volatility
If you're interested in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), then you might want to consider its beta (a...
- Zacks•10 days ago
Implied Volatility Surging for Intra-Cellular (ITCI) Stock Options
Investors need to pay close attention to Intra-Cellular (ITCI) stock based on the movements in the options market lately.
- TheStreet.com•last month
2 Biotech Names See Directors Direct Cash to Their Shares
The market suffered a sharp selloff on Monday as China announced new tariffs effective June 1 on $60 billion of imports from the U.S. That action was response to the Trump administration's decision the previous week to raise tariffs from 10% to 25% on $200 billion of imports from China after the Chinese delegation reneged on several key provisions of a new trade deal. The administration did mend fences on the trade front elsewhere to bring its full attention to bear on China. In addition, aluminum and steel tariffs on Canada were dropped.
- Thomson Reuters StreetEvents•last month
Edited Transcript of ITCI earnings conference call or presentation 8-May-19 12:30pm GMT
Q1 2019 Intra-Cellular Therapies Inc Earnings Call
- Simply Wall St.•2 months ago
Such Is Life: How Intra-Cellular Therapies (NASDAQ:ITCI) Shareholders Saw Their Shares Drop 57%
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
- Insider Monkey•2 months ago
Here’s What Hedge Funds Think About Intra-Cellular Therapies Inc (ITCI)
The elite funds run by legendary investors such as David Tepper and Dan Loeb make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don't follow. Because of their pay structures, they have strong incentives to do the research necessary […]
Motley Fool•2 months agoIntra-Cellular Therapies, Inc. (ITCI) Q1 2019 Earnings Call Transcript
ITCI earnings call for the period ending March 31, 2019.
- Associated Press•2 months ago
Intra-Cellular: 1Q Earnings Snapshot
The New York-based company said it had a loss of 63 cents per share. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a ...
- Zacks•2 months ago
Are Options Traders Betting on a Big Move in Intra-Cellular Therapies (ITCI) Stock?
Investors need to pay close attention to Intra-Cellular Therapies (ITCI) stock based on the movements in the options market lately.
- Simply Wall St.•3 months ago
Investors Who Bought Intra-Cellular Therapies (NASDAQ:ITCI) Shares Three Years Ago Are Now Down 61%
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! If you love investing in stocks you're bound to buy some losers. Long term Intra-Cellular Therapies, Inc. (NASDAQ:ITCI...
- Thomson Reuters StreetEvents•4 months ago
Edited Transcript of ITCI earnings conference call or presentation 27-Feb-19 1:30pm GMT
Q4 2018 Intra-Cellular Therapies Inc Earnings Call
Motley Fool•4 months agoIntra-Cellular Therapies Inc (ITCI) Q4 2018 Earnings Conference Call Transcript
ITCI earnings call for the period ending December 31, 2018.
- Investor's Business Daily•4 months ago
Here Are 5 Biotech Stocks To Love This Valentine's Day: Analyst
An RBC Capital Markets analyst is "head over heels" for five biotech stocks, two with high Relative Strength Ratings. In afternoon action in the stock market, biotech stocks inched up.
- Simply Wall St.•5 months ago
Read This Before Buying Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The flip side of that is that there are more Read More...
- Insider Monkey•6 months ago
Is Intra-Cellular Therapies Inc (ITCI) A Good Stock To Buy?
Many investors, including Paul Tudor Jones or Stan Druckenmiller, have been saying for a while now that the current market is overvalued due to a low interest rate environment that leads to companies swapping their equity for debt and focusing mostly on short-term performance such as beating the quarterly earnings estimates. In the fourth quarter, […]
- Simply Wall St.•6 months ago
How Should Investors React To Intra-Cellular Therapies, Inc.’s (NASDAQ:ITCI) CEO Pay?
Sharon Mates became the CEO of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) in 2013. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar Read More...
- Thomson Reuters StreetEvents•7 months ago
Edited Transcript of ITCI earnings conference call or presentation 7-Nov-18 1:30pm GMT
Q3 2018 Intra-Cellular Therapies Inc Earnings Call
- Simply Wall St.•8 months ago
Does Intra-Cellular Therapies Inc (NASDAQ:ITCI) Have A High Beta?
If you own shares in Intra-Cellular Therapies Inc (NASDAQ:ITCI) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...
- Associated Press•8 months ago
Intra-Cellular: 3Q Earnings Snapshot
On a per-share basis, the New York-based company said it had a loss of 76 cents. The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
- Zacks•8 months ago
Intra-Cellular Therapies Sees Hammer Chart Pattern: Time to Buy?
Intra-Cellular Therapies has been struggling lately, but the selling pressure may be coming to an end soon.
- Zacks•9 months ago
Options Traders Expect Huge Moves in Intra-Cellular (ITCI) Stock
Intra-Cellular (ITCI) needs investors to pay close attention to the stock based on moves in the options market lately.
- Simply Wall St.•9 months ago
Is Intra-Cellular Therapies Inc (NASDAQ:ITCI) A Financially Sound Company?
Zero-debt allows substantial financial flexibility, especially for small-cap companies like Intra-Cellular Therapies Inc (NASDAQ:ITCI), as the company does not have to adhere to strict debt covenants. However, it also facesRead More...
- Kiplinger•11 months ago
7 Biotech Stocks With Big Upcoming Catalysts
Are you ready? Biotech stocks provide a compelling opportunity for risk-tolerant investors looking for rich rewards. Regardless of market sentiment, economic data or trade wars, a key regulatory approval or trial data can send prices rocketing. Consider Madrigal Pharma (MDGL), which exploded by nearly 150% back in May following positive Phase 2 results for a liver-disease treatment. Of course, the opposite can also be true - prices can fall just as quickly if data or approvals fail to impress. That's why it's so crucial to conduct thorough research before investing in this high-potential (but high-risk) area of the market. For instance, using TipRanks, we can assess both the analyst consensus rating (all the stocks covered below are a "Moderate Buy" or "Strong Buy") and the expected upside potential based on recent ratings. Here are seven biotech stocks that could be catapulted higher by near-term catalysts. We'll also explore the pros' analysis and price targets for each company. SEE ALSO: The 18 Best Stocks to Buy for the Rest of 2018
